MCID: PYR039
MIFTS: 43

Peyronie Disease

Categories: Rare diseases, Reproductive diseases

Aliases & Classifications for Peyronie Disease

MalaCards integrated aliases for Peyronie Disease:

Name: Peyronie Disease 57 76 53 55 73
Penile Curvature 53

Characteristics:

OMIM:

57
Inheritance:
male-limited, autosomal dominant


Classifications:



External Ids:

OMIM 57 171000
MedGen 42 C0030848
SNOMED-CT via HPO 69 287085006 42030000

Summaries for Peyronie Disease

NIH Rare Diseases : 53 Peyronie disease is a connective tissue disorder characterized by a plaque, or hard lump, that forms within the penis. Affected individuals may experience painful, curved erections which can make make normal sexual intercourse impossible. Symptoms may appear suddenly or develop gradually. While the painful erections for most men resolve over time, the scar tissue and curvature may remain. Some cases appear to resolve spontaneously. The exact cause of Peyronie's disease is not known.

MalaCards based summary : Peyronie Disease, also known as penile curvature, is related to peyronie's disease and impotence. An important gene associated with Peyronie Disease is IFNA2 (Interferon Alpha 2), and among its related pathways/superpathways are Toll-like Receptor Signaling Pathway and Pathways in cancer. The drugs Acetylcholine and Lidocaine have been mentioned in the context of this disorder. Affiliated tissues include bone, prostate and small intestine, and related phenotypes are abnormality of the genitourinary system and abnormality of the skeletal system

Wikipedia : 76 Peyronie\'s disease is a connective tissue disorder involving the growth of fibrous plaques in the soft... more...

Description from OMIM: 171000

Related Diseases for Peyronie Disease

Diseases in the Peyronie Disease family:

Peyronie's Disease

Diseases related to Peyronie Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 18)
# Related Disease Score Top Affiliating Genes
1 peyronie's disease 31.3 IFNA2 TGFB1 TGFB2
2 impotence 29.7 NOS2 PDE5A
3 dupuytren contracture 10.9
4 ledderhose disease 10.9
5 giant hemangioma 10.2 IFNA2 TGFB1
6 spinal cord injury 10.0 NOS2 TGFB1
7 anoxia 9.9 NOS2 SOD1
8 retinal vasculitis 9.9 NOS2 SOD1
9 pneumoconiosis 9.8 SOD1 TGFB1
10 ureteral obstruction 9.8 NOS2 TGFB1
11 eales disease 9.8 NOS2 SOD1
12 stiff skin syndrome 9.8 TGFB1 TGFB2
13 mucositis 9.7
14 tuberculoid leprosy 9.7 TGFB1 TGFB2
15 chagas disease 9.7 NOS2 TGFB1
16 vitreoretinopathy, neovascular inflammatory 9.7 TGFB1 TGFB2
17 penile disease 9.6 IFNA2 PDE5A TGFB1
18 uveitis 9.1 IFNA2 TGFB2

Graphical network of the top 20 diseases related to Peyronie Disease:



Diseases related to Peyronie Disease

Symptoms & Phenotypes for Peyronie Disease

Symptoms via clinical synopsis from OMIM:

57
GU:
penile contracture

Limbs:
associated dupuytren contracture


Clinical features from OMIM:

171000

Human phenotypes related to Peyronie Disease:

32
# Description HPO Frequency HPO Source Accession
1 abnormality of the genitourinary system 32 HP:0000119
2 abnormality of the skeletal system 32 HP:0000924

MGI Mouse Phenotypes related to Peyronie Disease:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 muscle MP:0005369 8.92 NOS2 SOD1 TGFB1 TGFB2

Drugs & Therapeutics for Peyronie Disease

Drugs for Peyronie Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 45)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetylcholine Approved Phase 2 51-84-3 187
2
Lidocaine Approved, Vet_approved Phase 2 137-58-6 3676
3 abobotulinumtoxinA Phase 2
4 Botulinum Toxins Phase 2
5 Botulinum Toxins, Type A Phase 2
6 Cholinergic Agents Phase 2
7 Neuromuscular Agents Phase 2
8 Neurotransmitter Agents Phase 2
9 onabotulinumtoxinA Phase 2
10 Peripheral Nervous System Agents Phase 2
11 Pharmaceutical Solutions Phase 2
12 Anesthetics Phase 2
13 Anesthetics, Local Phase 2
14 Anti-Arrhythmia Agents Phase 2
15 Central Nervous System Depressants Phase 2
16 Diuretics, Potassium Sparing Phase 2
17 Sodium Channel Blockers Phase 2
18
Methyltestosterone Approved Phase 1 58-18-4 6010
19
Testosterone Approved, Investigational Phase 1 58-22-0 6013
20
Testosterone enanthate Approved Phase 1 315-37-7 9416
21
Testosterone undecanoate Approved, Investigational Phase 1 5949-44-0
22
Ergocalciferol Approved, Nutraceutical Phase 1 50-14-6 5280793
23
Tocopherol Approved, Investigational, Nutraceutical Phase 1 1406-66-2 14986
24
Vitamin D Approved, Nutraceutical, Vet_approved Phase 1 1406-16-2
25
Vitamin E Approved, Nutraceutical, Vet_approved Phase 1 59-02-9 14985
26 Anabolic Agents Phase 1
27 Androgens Phase 1
28 Antineoplastic Agents, Hormonal Phase 1
29 Antioxidants Phase 1
30 Bone Density Conservation Agents Phase 1
31 Ergocalciferols Phase 1
32 Hormone Antagonists Phase 1
33 Hormones Phase 1
34 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 1
35 Micronutrients Phase 1
36 Protective Agents Phase 1
37 Testosterone 17 beta-cypionate Phase 1
38 Tocopherols Phase 1
39 Tocotrienols Phase 1
40 Trace Elements Phase 1
41 Vitamins Phase 1
42 Calciferol Nutraceutical Phase 1
43 Tocotrienol Investigational, Nutraceutical Phase 1 6829-55-6
44 Vitamin D2 Nutraceutical Phase 1
45 Phosphodiesterase 5 Inhibitors

Interventional clinical trials:

(show all 22)
# Name Status NCT ID Phase Drugs
1 A Phase 3, Open-label Study of the Safety and Effectiveness of AA4500 Administered Twice Per Treatment Cycle for up to Four Treatment Cycles (2 x 4) in Men With Peyronie's Disease Completed NCT01685437 Phase 3
2 A Study of AA4500 in Men With Peyronie's Disease Completed NCT01243411 Phase 3
3 Study of AA4500 in the Treatment of Peyronie's Disease Completed NCT01221597 Phase 3
4 Study of AA4500 in the Treatment of Peyronie's Disease Completed NCT01221623 Phase 3
5 An Open-label Study to Assess the Safety and Effectiveness of AA4500 in Combination With the ErecAid® Esteem® Manual Vacuum Therapy System in Treating Men With Peyronie's Disease Completed NCT02267460 Phase 3
6 Dupuytren's Disease and Extracorporeal Shockwave Therapy (DupuyShock-2010) Unknown status NCT01184586 Phase 2
7 The Safety and Effectiveness of AA4500 in Subjects With Peyronie's Disease Completed NCT00755222 Phase 2
8 Pharmacokinetics of a Single Treatment Cycle of AA4500 0.58 mg in Men With Peyronie's Disease Completed NCT01430169 Phase 2
9 H-22411: BOTOX® for Peyronie's Disease Recruiting NCT00812838 Phase 2 100 units of Botulinum Toxin Type A
10 Intracavernosal Injection of Botulinum Toxin Type A (50 and 100 Unit) in the Treatment of Erectile Dysfunction Enrolling by invitation NCT03355963 Phase 2
11 Clostridium Histolyticum Collagenase Injection for Urethral Disease Not yet recruiting NCT02948842 Phase 2 Clostridium Histolyticum Collagenase;Lidocaine
12 Peyronie's Disease Treatment Protocol Completed NCT02072018 Phase 1 H-100;Placebo
13 Testosterone Pellets Plus Vitamin D and E Versus Vitamin D and E Alone for the Treatment of Peyronie's Disease Completed NCT01578473 Phase 1 Vitamin D2;Vitamin E;Testosterone Pellets
14 Evaluate the Safety and Feasibility of Injecting PMD-MSC Into the Penis to Treat the Symptoms of PD Completed NCT02395029 Phase 1
15 Management of Peyronie's Disease With Adipose Tissue Stem Cell Unknown status NCT02414308 Not Applicable Adipose tissue stem cell injection
16 Efficacy of Extracorporal Shock Wave Therapy in Patient With Chronic Non-bacterial Prostatitis / Chronic Pelvic Pain Syndrome Unknown status NCT01714830 Not Applicable
17 Long-term Safety, Curvature Deformity Characterization, and Immunogenicity Over Time in Subjects Previously Treated With AA4500 for Peyronies Disease Completed NCT02298829 Subjects Previously Treated with AA4500
18 Change in Penile Length Following Bilateral Nerve-Sparing Radical Prostatectomy Completed NCT00800813
19 Low-Intensity Extracorporeal Shockwave Therapy and Vacuum Erectile Device as a Treatment for Peyronies Disease. Recruiting NCT03530540 Not Applicable
20 Efficacy of Penile Traction Therapy Using a Novel Device Recruiting NCT03389854 Not Applicable
21 Penile Length Maintenance Post-Prostatectomy Recruiting NCT03500419 Not Applicable
22 Outcomes of Surgical Correction of Penile Curvature in Adult Not yet recruiting NCT03313986

Search NIH Clinical Center for Peyronie Disease

Genetic Tests for Peyronie Disease

Anatomical Context for Peyronie Disease

MalaCards organs/tissues related to Peyronie Disease:

41
Bone, Prostate, Small Intestine

Publications for Peyronie Disease

Articles related to Peyronie Disease:

(show all 29)
# Title Authors Year
1
Re: Clinical Experience with Penile Traction Therapy among Men Undergoing Collagenase Clostridium Histolyticum for Peyronie Disease. ( 29310171 )
2018
2
Separating the Wheat From the Chaff: An Evaluation of Readability, Quality, and Accuracy of Online Health Information for Treatment of Peyronie Disease. ( 29723588 )
2018
3
Penile Reconstructive Surgery in Peyronie Disease: Challenges in Restoring Normal Penis Size, Shape, and Function. ( 29623703 )
2018
4
A Novel Noninvasive Ultrasound Vibro-elastography Technique for Assessing Patients With Erectile Dysfunction and Peyronie Disease. ( 29548864 )
2018
5
Clinical Experience With Penile Traction Therapy Among Men Undergoing Collagenase Clostridium histolyticum for Peyronie Disease. ( 28347795 )
2017
6
Small Intestinal Submucosa Grafting for Peyronie Disease: Outcomes and Patient Satisfaction. ( 27825744 )
2017
7
Factors Associated With Erectile Dysfunction and the Peyronie's Disease Questionnaire in Patients With Peyronie Disease. ( 28554517 )
2017
8
Safety Profile of Collagenase Clostridium Histolyticum Stratified by Degree of Penile Curvature in Patients With Peyronie Disease. ( 28502596 )
2017
9
Re: Factors Associated with Erectile Dysfunction and the Peyronie's Disease Questionnaire in Patients with Peyronie Disease. ( 29144914 )
2017
10
Self-reported Clinical Meaningfulness Early in the Treatment Course Predicts Objective Outcomes in Men Undergoing Collagenase Clostridium histolyticum Injections for Peyronie Disease. ( 28483591 )
2017
11
Re: Clinical Experience with Penile Traction Therapy among Men Undergoing Collagenase Clostridium histolyticum for Peyronie Disease. ( 28817884 )
2017
12
Re: Small Intestinal Submucosa Grafting for Peyronie Disease: Outcomes and Patient Satisfaction. ( 29059762 )
2017
13
Partial Plaque Excision and Grafting With Collagen Fleece in Peyronie Disease. ( 26953837 )
2016
14
The Genetic Basis of Peyronie Disease: A Review. ( 27872008 )
2016
15
Effects of Stem Cell Treatment in Human Patients With Peyronie Disease. ( 26414724 )
2015
16
Re: Corporoplasty Using Buccal Mucosa Graft in Peyronie Disease: Is it a First Choice? ( 26088238 )
2015
17
Corporoplasty using buccal mucosa graft in Peyronie disease: is it a first choice? ( 25582815 )
2015
18
Intralesional Injections for Early Peyronie Disease: Standardized Assessment and Analysis of Predictive Factors for Treatment Response. ( 26142583 )
2015
19
Lingual mucosal graft in treatment of Peyronie disease. ( 25283703 )
2014
20
The anti-inflammatory and antifibrosis effects of anthocyanin extracted from black soybean on a Peyronie disease rat model. ( 25156514 )
2014
21
Re: clinical efficacy, safety and tolerability of collagenase clostridium histolyticum for the treatment of peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies. ( 24289857 )
2014
22
[Medico legal considerations on prosthesis surgery of the erectile dysfunction in a La Peyronie disease case]. ( 23612236 )
2013
23
The non-surgical treatment of peyronie disease: 2013 update. ( 24459651 )
2013
24
Peyronie disease in association with carvedilol: a case report. ( 19088529 )
2008
25
Evidence that osteogenic progenitor cells in the human tunica albuginea may originate from stem cells: implications for peyronie disease. ( 16093362 )
2005
26
Physical treatment of Peyronie disease. ( 11475478 )
2001
27
On the therapy of induratio penis plastica (Peyronies disease) by means of radium moulages. ( 3969691 )
1985
28
Surgical considerations in treatment of Peyronie disease. ( 6986705 )
1980
29
Is it worthwhile to treat Peyronie disease? ( 7395000 )
1980

Variations for Peyronie Disease

Expression for Peyronie Disease

Search GEO for disease gene expression data for Peyronie Disease.

Pathways for Peyronie Disease

Pathways related to Peyronie Disease according to GeneCards Suite gene sharing:

(show all 30)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.59 IFNA2 NOS2 TGFB1 TGFB2
2 12.28 IFNA2 NOS2 TGFB1 TGFB2
3
Show member pathways
12.23 IFNA2 TGFB1 TGFB2
4
Show member pathways
12.18 IFNA2 NOS2 PDE5A SOD1 TGFB1 TGFB2
5
Show member pathways
11.85 NOS2 TGFB1 TGFB2
6 11.76 NOS2 TGFB1 TGFB2
7 11.6 TGFB1 TGFB2
8 11.59 TGFB1 TGFB2
9 11.56 TGFB1 TGFB2
10 11.55 NOS2 SOD1
11 11.51 IFNA2 NOS2 TGFB1 TGFB2
12 11.5 IFNA2 TGFB1
13
Show member pathways
11.49 TGFB1 TGFB2
14 11.44 NOS2 SOD1
15 11.42 TGFB1 TGFB2
16 11.4 TGFB1 TGFB2
17
Show member pathways
11.37 NOS2 SOD1
18 11.35 TGFB1 TGFB2
19 11.32 NOS2 TGFB2
20 11.31 NOS2 TGFB1 TGFB2
21 11.3 TGFB1 TGFB2
22 11.27 NOS2 TGFB1
23 11.25 TGFB1 TGFB2
24 11.24 TGFB1 TGFB2
25
Show member pathways
11.15 NOS2 PDE5A
26
Show member pathways
11.15 TGFB1 TGFB2
27
Show member pathways
11.11 NOS2 SOD1
28 11.06 IFNA2 NOS2
29 10.95 TGFB1 TGFB2
30 10.44 NOS2 PDE5A

GO Terms for Peyronie Disease

Cellular components related to Peyronie Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 platelet alpha granule lumen GO:0031093 9.16 TGFB1 TGFB2
2 neuronal cell body GO:0043025 9.13 SOD1 TGFB1 TGFB2
3 extracellular matrix GO:0031012 8.8 SOD1 TGFB1 TGFB2

Biological processes related to Peyronie Disease according to GeneCards Suite gene sharing:

(show all 35)
# Name GO ID Score Top Affiliating Genes
1 regulation of signaling receptor activity GO:0010469 9.83 IFNA2 TGFB1 TGFB2
2 inflammatory response GO:0006954 9.81 IFNA2 NOS2 TGFB1
3 cytokine-mediated signaling pathway GO:0019221 9.76 IFNA2 NOS2 TGFB1
4 response to drug GO:0042493 9.73 SOD1 TGFB1 TGFB2
5 regulation of cell proliferation GO:0042127 9.7 NOS2 TGFB1 TGFB2
6 wound healing GO:0042060 9.67 TGFB1 TGFB2
7 neural tube closure GO:0001843 9.66 TGFB1 TGFB2
8 response to wounding GO:0009611 9.66 TGFB1 TGFB2
9 positive regulation of MAP kinase activity GO:0043406 9.65 PDE5A TGFB1
10 negative regulation of epithelial cell proliferation GO:0050680 9.65 TGFB1 TGFB2
11 SMAD protein signal transduction GO:0060395 9.64 TGFB1 TGFB2
12 cell development GO:0048468 9.64 TGFB1 TGFB2
13 regulation of MAPK cascade GO:0043408 9.63 TGFB1 TGFB2
14 inner ear development GO:0048839 9.62 TGFB1 TGFB2
15 positive regulation of pathway-restricted SMAD protein phosphorylation GO:0010862 9.62 TGFB1 TGFB2
16 positive regulation of cell division GO:0051781 9.61 TGFB1 TGFB2
17 positive regulation of epithelial to mesenchymal transition GO:0010718 9.61 TGFB1 TGFB2
18 extrinsic apoptotic signaling pathway GO:0097191 9.6 TGFB1 TGFB2
19 response to progesterone GO:0032570 9.59 TGFB1 TGFB2
20 positive regulation of protein secretion GO:0050714 9.58 TGFB1 TGFB2
21 response to hypoxia GO:0001666 9.58 NOS2 TGFB1 TGFB2
22 negative regulation of T cell proliferation GO:0042130 9.57 PDE5A TGFB1
23 epithelial to mesenchymal transition GO:0001837 9.55 TGFB1 TGFB2
24 negative regulation of immune response GO:0050777 9.54 TGFB1 TGFB2
25 positive regulation of pri-miRNA transcription by RNA polymerase II GO:1902895 9.51 TGFB1 TGFB2
26 platelet degranulation GO:0002576 9.5 SOD1 TGFB1 TGFB2
27 cell-cell junction organization GO:0045216 9.49 TGFB1 TGFB2
28 superoxide metabolic process GO:0006801 9.48 NOS2 SOD1
29 cell growth GO:0016049 9.46 TGFB1 TGFB2
30 positive regulation of superoxide anion generation GO:0032930 9.43 SOD1 TGFB1
31 pathway-restricted SMAD protein phosphorylation GO:0060389 9.37 TGFB1 TGFB2
32 salivary gland morphogenesis GO:0007435 9.26 TGFB1 TGFB2
33 heart valve morphogenesis GO:0003179 9.16 TGFB1 TGFB2
34 negative regulation of macrophage cytokine production GO:0010936 8.96 TGFB1 TGFB2
35 negative regulation of gene expression GO:0010629 8.92 IFNA2 NOS2 TGFB1 TGFB2

Molecular functions related to Peyronie Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein homodimerization activity GO:0042803 9.62 NOS2 SOD1 TGFB1 TGFB2
2 cytokine activity GO:0005125 9.43 IFNA2 TGFB1 TGFB2
3 transforming growth factor beta receptor binding GO:0005160 9.37 TGFB1 TGFB2
4 BMP receptor binding GO:0070700 9.16 TGFB1 TGFB2
5 type II transforming growth factor beta receptor binding GO:0005114 8.96 TGFB1 TGFB2
6 type III transforming growth factor beta receptor binding GO:0034714 8.62 TGFB1 TGFB2

Sources for Peyronie Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....